Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …
heterogeneity of this disease presents a big challenge in its therapeutic management …
Cell cycle control in cancer
HK Matthews, C Bertoli, RAM de Bruin - Nature reviews Molecular cell …, 2022 - nature.com
Cancer is a group of diseases in which cells divide continuously and excessively. Cell
division is tightly regulated by multiple evolutionarily conserved cell cycle control …
division is tightly regulated by multiple evolutionarily conserved cell cycle control …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Ribociclib plus endocrine therapy in early breast cancer
D Slamon, O Lipatov, Z Nowecki… - … England Journal of …, 2024 - Mass Medical Soc
Background Ribociclib has been shown to have a significant overall survival benefit in
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
Background Among breast cancers without human epidermal growth factor receptor 2
(HER2) amplification, overexpression, or both, a large proportion express low levels of …
(HER2) amplification, overexpression, or both, a large proportion express low levels of …
Targeting CDK4 and CDK6 in cancer
S Goel, JS Bergholz, JJ Zhao - Nature Reviews Cancer, 2022 - nature.com
Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …
transition into S phase and are important for the initiation, growth and survival of many …
Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, J Abraham, R Aft… - Journal of the National …, 2020 - jnccn.org
Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …
breast cancer, which have led to improvements in survival. In addition to patient and clinical …
Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences
CL Braal, EM Jongbloed, SM Wilting, RHJ Mathijssen… - Drugs, 2021 - Springer
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …